Global Chronic Kidney Disease (CKD) Pipeline Landscape Report 2022: Comprehensive Insights About 50+ Companies and 50+ Pipeline Drugs - ResearchAndMarkets.com

The "Chronic Kidney Disease (CKD) - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

This "Chronic-kidney-disease-chronic-renal-failure- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic-kidney-disease-chronic-renal-failure pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

A detailed picture of the Chronic-kidney-disease-chronic-renal-failure pipeline landscape is provided which includes the disease overview and Chronic-kidney-disease-chronic-renal-failure treatment guidelines.

The assessment part of the report embraces, in depth Chronic-kidney-disease-chronic-renal-failure commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic-kidney-disease-chronic-renal-failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic-kidney-disease-chronic-renal-failure R&D. The therapies under development are focused on novel approaches to treat/improve Chronic-kidney-disease-chronic-renal-failure.

Chronic-kidney-disease-chronic-renal-failure Emerging Drugs Chapters

This segment of the Chronic-kidney-disease-chronic-renal-failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic-kidney-disease-chronic-renal-failure Emerging Drugs

KBP-5074: KBP Biosciences

KBP Biosciences' lead product candidate, KBP-5074, is a potentially best-in-class, next-generation, non-steroidal MRA discovered and developed by KBP's scientists, is being developed globally to initially treat Stage 3b/4, or moderate-to-severe, CKD patients with uncontrolled hypertension. KBP-5074 selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors, suggesting that KBP-5074 should be effective in blocking the hypertensive and renal tissue damaging effects of aldosterone with reduced risk of pro-diabetic and adverse endocrine effects. In clinical trials conducted to-date, it has demonstrated an ability to lower blood pressure without androgenic effects such as hirsutism, obesity and gynecomastia. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Uncontrolled Hypertension and Moderate or Severe CKD.

Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company

Empagliflozin (BI10773) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for chronic kidney disease.

ALLN-346: Allena Pharmaceuticals

ALLN-346 is an investigational first-in-class, non-absorbed, orally administered enzyme for the treatment of hyperuricemia and gout, a metabolic disorder characterized by high systemic levels of urate that can lead to several complications, including arthritis, kidney stones, and CKD.

US-APR2020: Kibow Pharma

US-APR2020 is a natural probiotics formulation that metabolizes nitrogenous waste, which generally diffuses from the circulating bloodstream into the bowel. When these waste products accumulate in high concentrations in the blood, they become highly toxic and can cause severe damage to many organ systems if they are not properly excreted. US-APR2020 utilizes nitrogenous wastes as nutrients. As probiotics grow and multiply, they consume more nitrogenous waste and effectively maintain healthy kidney function.

MEDI8367: AstraZeneca

Medi8367 is an antibody which is used to treat Chronic Kidney Disease. It specifically binds human integrin ?8 and works allosterically reducing its affinity for the LAP domain, hence preventing ?8-mediated TGF? activation but not its cell adhesion function.

Chronic-kidney-disease-chronic-renal-failure: Therapeutic Assessment

This segment of the report provides insights about the different Chronic-kidney-disease-chronic-renal-failure drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic-kidney-disease-chronic-renal-failure

There are approx. 50+ key companies which are developing the therapies for Chronic-kidney-disease-chronic-renal-failure. The companies which have their Chronic-kidney-disease-chronic-renal-failure drug candidates in the most advanced stage, i.e. phase III include, KBP Biosciences.

Chronic-kidney-disease-chronic-renal-failure: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic-kidney-disease-chronic-renal-failure therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic-kidney-disease-chronic-renal-failure drugs.

Key Questions Answered

• How many companies are developing Chronic-kidney-disease-chronic-renal-failure drugs?
• How many Chronic-kidney-disease-chronic-renal-failure drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic-kidney-disease-chronic-renal-failure?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic-kidney-disease-chronic-renal-failure therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic-kidney-disease-chronic-renal-failure and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• KBP Biosciences
• Eli Lilly and Company
• Novo Nordisk
• Prokidney
• Boryung Pharmaceutical
• Boehringer Ingelheim
• Cadila Healthcare Limited
• AM-Pharma
• DiaMedica Therapeutics
• Allena Pharmaceuticals
• AstraZeneca
• Kibow Pharma
• Bayer
• Roche
• Caladrius Biosciences
• UnicoCell Biomed
• Scohia Pharma
• Unicycive Therapeutics
• Senda Biosciences
• Sarfez Pharmaceuticals
• Rege Nephro
• Orgenesis
• Oisin Biotechnologies
• Aria Pharmaceuticals
• RedHill Biopharma
• BERGENBIO
• GNI Group

Key Products

• KBP-5074
• Ziltivekimab
• Semaglutide
• Fimasartan
• Empagliflozin
• Ilofotase alfa
• DM199
• ALLN-346
• Zibotentan
• Verinurad
• US-APR2020
• Runcaciguat
• Pirfenidone
• BI-685509
• AZD9977
• AZD5718
• ELIXCYTE
• MEDI8367
• Cellgram-CKD
• AZD8233
• SCO-116

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/q1trnx

View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005629/en/